ICAD - iCAD, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.20
+0.02 (+0.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.18
Open3.14
Bid2.70 x 1800
Ask4.25 x 1000
Day's Range3.14 - 3.25
52 Week Range2.93 - 4.89
Volume21,515
Avg. Volume28,828
Market Cap53.322M
Beta0.71
PE Ratio (TTM)N/A
EPS (TTM)-1.04
Earnings DateMay 4, 2017 - May 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • GlobeNewswire18 days ago

    iCAD Named 2018 MedTech Breakthrough Award Winner

    NASHUA, N.H., June 06, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its PowerLook® Tomo Detection solution has been selected as the winner of the “Best New Radiology Solution” award by MedTech Breakthrough, an independent organization recognizing the top companies, technologies and products in the global health and medical technology market.

  • Zacks Small Cap Researchlast month

    ICAD: Q1 2018 Results: Detection Disappointing But Still Looking For 2.0-Related Inflection in 2H

    While Therapy revenue was just about dead-on with what we had been expecting, Detection revenue was quite disappointing. Detection revenue was 15% lower than where we thought it would come in, with almost all of the miss related to product sales. While we had anticipated Detection revenue would contract sequentially given some lumpiness in Q4 ’17, we did think tomo-related momentum would result in solid double-digit yoy growth in product sales in that segment.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ICAD earnings conference call or presentation 14-May-18 8:30pm GMT

    Q1 2018 ICAD Inc Earnings Call

  • Associated Presslast month

    Icad: 1Q Earnings Snapshot

    The Nashua, New Hampshire-based company said it had a loss of 20 cents per share. Losses, adjusted for severance costs and non-recurring costs, were 19 cents per share. The imaging and early cancer detection ...

  • GlobeNewswirelast month

    iCAD Reports First Quarter 2018 Financial Results

    Company Expects to Submit PowerLook Tomo Detection Version 2.0 for FDA Approval Shortly Submission to be Based on Promising Results from Pivotal Clinical Reader Study. Conference call today at 4:30 p.m. ...

  • ACCESSWIRElast month

    iCAD, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / iCAD, Inc. (NASDAQ: ICAD ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 4:30 PM Eastern Time. To listen to ...

  • iCAD Inc (NASDAQ:ICAD): Time For A Financial Health Check
    Simply Wall St.last month

    iCAD Inc (NASDAQ:ICAD): Time For A Financial Health Check

    iCAD Inc (NASDAQ:ICAD) is a small-cap stock with a market capitalization of US$62.32M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...

  • GlobeNewswire2 months ago

    iCAD to Report First Quarter 2018 Financial Results on Monday, May 14, 2018

    NASHUA, N.H., May 08, 2018-- iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced ...

  • GlobeNewswire2 months ago

    iCAD Announces Presentation of Positive Clinical Data on Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers at ESTRO 37

    ESTRO Booth 6800 -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that researchers from Hospital Universitario Miguel Servet in Zaragoza, Spain will present new results from three clinical studies supporting the efficacy of the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer and gynecological cancers during the European Society for Radiotherapy & Oncology (ESTRO 37) meeting at the Barcelona International Convention Centre in Barcelona, Spain. The Xoft System is a proprietary eBx platform designed to deliver isotope-free (non-radioactive) radiation therapy.

  • ACCESSWIRE2 months ago

    Free Post Earnings Research Report: Nutanix’s Revenues Surged 44%; Net Loss Narrowed

    Stock Monitor: iCAD Inc. Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors.com has just released a free earnings report on Nutanix, Inc. (NASDAQ: NTNX ). If you want access ...

  • Zacks Small Cap Research3 months ago

    ICAD: Q4 2017 Results: Tomo Seeing “Strong Demand”. Plug Pulled on Unprofitable Skin Subscription Biz

    Revenue, particularly in the Detection segment, continued to impress with very strong sales of the tomo (2D and 3D) products pushing total revenue up by 14% yoy. Detection product sales, up 100% yoy (pro-forma for ex-MRI), turned in the best quarter since Q3 2011 (when ICAD was still direct-selling MRI software) and crushed our number by 25%. While Q4 is typically ICAD’s strongest, the apparent accelerating adoption of the ‘legacy’ 2D and first-gen 3D tomo (GE-only) applications is obviously encouraging, particularly given the near-term launch of ICAD’s next-gen software.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of ICAD earnings conference call or presentation 22-Mar-18 8:30pm GMT

    Q4 2017 ICAD Inc Earnings Call

  • InvestorPlace3 months ago

    3 Stocks to Watch on Friday: At Home Group Inc (HOME), HTG Molecular Diagnostics Inc (HTGM) and iCAD Inc (ICAD)

    The Dow Jones Industrial Average dropped more than 700 points on a down day for U.S. equities in which President Donald Trump announced tariffs on international imports from China. The index fell 2.9% Thursday, while the S&P 500 Index fell 2.5% and the Nasdaq Composite fell 2.4%.

  • ACCESSWIRE3 months ago

    iCAD, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 22, 2018 / iCAD, Inc. (NASDAQ: ICAD ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 22, 2018, at 4:30 PM Eastern Time. To listen ...

  • Zacks Small Cap Research6 months ago

    ICAD: Study Shows IORT Superior To EBRT in Quality of Life, Cost

    By Brian Marckx, CFA NASDAQ:ICAD Decision-Tree Analysis of Published Studies Indicates IORT Superior To EBRT in QoL, Cost:   A study which was recently published in Cost Effectiveness and Resource Allocation ...

  • Are iCAD Inc’s (ICAD) Interest Costs Too High?
    Simply Wall St.7 months ago

    Are iCAD Inc’s (ICAD) Interest Costs Too High?

    While small-cap stocks, such as iCAD Inc (NASDAQ:ICAD) with its market cap of USD $58.45M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of ICAD earnings conference call or presentation 8-Nov-17 9:30pm GMT

    Q3 2017 ICAD Inc Earnings Call

  • Zacks Small Cap Research7 months ago

    ICAD: Q3 Detection and Therapy Results Solid. Tomo Growth To Accelerate

    By Brian Marckx, CFA NASDAQ:ICAD Q3 2017 Results:  Revenue Dead-On With Our Estimate. Solid Results From Both Detection and Therapy… iCAD (NASDAQ:ICAD) reported Q3 financial results for their third quarter ...